Similarly, patients with TCR MM and a duration of response on the index anti-CD38 mAb containing regimen of less than 1 year had a trend towards a shorter PFS (161/199 [81%], median PFS 3.9 [95% CI 3.0–5.1] months) compared to patients with a response of ≥1 year (38/199 [19%], median PFS 6.1 [95% CI 3.9–7.3] months). This evidence concerns the gene CD38 and Miyoshi myopathy.